NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI)
Pifeltro is a prescription drug approved by the Food and Drug Administration (FDA) to treat HIV-1 infection in adults who have not previously received antiretroviral treatment. Pifeltro is recommended to be used in combination with other antiretroviral medications. Pifeltro is also referred to by its drug name, Doravirine, and by the abbreviation DOR. Doravirine is a component of the combination drug Delstrigo.
Pifeltro is an antiviral medication of the non-nucleoside reverse transcriptase inhibitor (NNRTI) class. Pifeltro is believed to work by preventing HIV from replicating in cells.
How do I take it?
Prescribing information states that Pifeltro is taken once or twice daily.
Pifeltro comes in tablet form.
The FDA-approved label for Pifeltro lists common side effects including headache, fatigue, dizziness, nausea, diarrhea, abdominal pain, and unusual dreams.
Rare but serious side effects listed for Pifeltro include immune reconstitution syndrome (an inflammatory disorder).
For more details about this treatment, visit:
Pifeltro – Merck